These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 18648190

  • 1. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR, Luttkopf D, Seitz R, Vieths S.
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [Abstract] [Full Text] [Related]

  • 2. Regulatory environment for allergen-specific immunotherapy.
    Kaul S, May S, Lüttkopf D, Vieths S.
    Allergy; 2011 Jun; 66(6):753-64. PubMed ID: 21288251
    [Abstract] [Full Text] [Related]

  • 3. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F.
    Bull Mem Acad R Med Belg; 2000 Jun; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [Abstract] [Full Text] [Related]

  • 4. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S, Sucić AF, Martinac AI.
    Regul Toxicol Pharmacol; 2010 Jun; 57(2-3):325-32. PubMed ID: 20385190
    [Abstract] [Full Text] [Related]

  • 5. European regulations relevant to the marketing and use of fish vaccines.
    Lee A.
    Dev Biol Stand; 1997 Jun; 90():341-6. PubMed ID: 9270862
    [Abstract] [Full Text] [Related]

  • 6. [Europe and medicines: role of the EMEA].
    Sauer F.
    Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
    [Abstract] [Full Text] [Related]

  • 7. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA.
    Ugeskr Laeger; 2003 Apr 14; 165(16):1648-9. PubMed ID: 12756819
    [Abstract] [Full Text] [Related]

  • 8. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, Bagnulo S, Reggio S, Rondini G.
    Eur J Clin Pharmacol; 2002 Nov 14; 58(8):495-500. PubMed ID: 12451425
    [Abstract] [Full Text] [Related]

  • 9. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A, Pieters L, Apers S.
    Planta Med; 2009 Jun 14; 75(7):683-8. PubMed ID: 19204891
    [Abstract] [Full Text] [Related]

  • 10. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS, Cichutek K.
    Dev Biol (Basel); 2000 Jun 14; 104():53-6. PubMed ID: 11713824
    [Abstract] [Full Text] [Related]

  • 11. [Allergens for specific immunotherapy: authorization and quality criteria of the Paul-Ehrlich-Institut].
    May S, Kaul S, Schröder C, Vieths S.
    Hautarzt; 2006 Oct 14; 57(10):867-74. PubMed ID: 16977441
    [Abstract] [Full Text] [Related]

  • 12. Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline.
    Gödicke V, Hundt F.
    Allergy; 2010 Dec 14; 65(12):1499-505. PubMed ID: 20608914
    [Abstract] [Full Text] [Related]

  • 13. Quality of alcohol-based hand disinfectants and their regulatory status. Development and marketing authorisation.
    Stengele M.
    J Hosp Infect; 2008 Oct 14; 70 Suppl 1():49-54. PubMed ID: 18994682
    [Abstract] [Full Text] [Related]

  • 14. [Excipients: regulatory aspects].
    Artiges A.
    Therapie; 1999 Oct 14; 54(1):15-9. PubMed ID: 10216417
    [Abstract] [Full Text] [Related]

  • 15. [European drug policy].
    Sauer F.
    Bull Mem Acad R Med Belg; 1993 Oct 14; 148(5-6):207-12; discussion 212-6. PubMed ID: 8142930
    [Abstract] [Full Text] [Related]

  • 16. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P, Schuessler-Lenz M, Ruiz S, Celis P, Reischl I, Menezes-Ferreira M, Flory E, Renner M, Ferry N.
    Adv Exp Med Biol; 2015 Oct 14; 871():103-30. PubMed ID: 26374215
    [Abstract] [Full Text] [Related]

  • 17. The harmonization of the regulation of blood products: a European perspective.
    Seitz R, Heiden M, Nübling CM, Unger G, Löwer J.
    Vox Sang; 2008 May 14; 94(4):267-76. PubMed ID: 18179678
    [Abstract] [Full Text] [Related]

  • 18. [National and European drug approval procedures].
    Mohrbutter KP.
    Z Arztl Fortbild Qualitatssich; 1997 Nov 14; 91(7):593-6. PubMed ID: 9527447
    [Abstract] [Full Text] [Related]

  • 19. The EAMG position on the regulation of existing products for treatment with special reference to named patient products (NPPs).
    Kroon AM.
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003 Nov 14; (94):7-14; discussion 14-6. PubMed ID: 15119017
    [Abstract] [Full Text] [Related]

  • 20. Current guidelines applicable for the approval of topically applied dermatological drugs in the EU.
    Straube MD, Zesch A.
    Fundam Clin Pharmacol; 2004 Oct 14; 18(5):503-11. PubMed ID: 15482371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.